Shares now are down over 98% from 2013 highs. quotes delayed at least 15 minutes, all others at least 20 minutes. Sign Up. All rights reserved. Gold Prices: Yesterday’s Rally Put Our ‘Trade of the Decade’ on Sale, Investors Are Buying this Dip, and You Can Sell Puts on Logitech, Stock Market Live Updates Wednesday: The Dow Flips Into the Red to Close the Day, 7 Dow Jones Stocks to Buy for the Post-Election Surge, 7 High-Yield Dividend Companies to Invest in During the Pandemic, 9 Cyclical Stocks With Further Gains to Come, Safely Trading NIO Stock Ahead Of High-Expectation Earnings. The issue was that the placebo worked nearly as well. Eli Lilly (LLY), Regeneron (REGN), Arcturus (ARCT) & Altimmune (ALT) Also In Advance Stages... Biden’s victory And Vaccine News Drove U.S. Indices On Monday Higher, The Future Growth Of Netflix Will Come From India And Other Significant Asian Markets, Goldman Sachs forecast low growth due to intense 2nd wave of Virus, No “blue wave” Scenario Pushing the Market Up. But possible is not the same as likely: ACST stock at this point looks like a ‘Hail Mary’ play. Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. On Jan. 13, Acasti disclosed topline results for its TRILOGY 1 Phase 3 trial of CaPre. For Acasti Pharma Inc. (ACST), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2. read more > view Acasti Pharma Inc Mackie sees sales potential of Acasti's CaPre drug, maintains Speculative Buy rating. Eli Lilly and Company (LLY) was up 2.9% on Tuesday. Short term estimates and forecasts for American International Group, Inc. (AIG), 3.16% jump drives, Inc. (JD) into becoming a top stock for investors. All rights reserved. The cause of the disappointing trial isn’t yet clear to Acasti itself. And if Acasti stumbles on either front, there’s little value left. Splitting up the data highlights that, out of 3 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. Acasti Pharma (NASDAQ:ACST) is running out of time, and running out of chances. It was only in late December that the shares were fetching $2.87, up from $1 a year earlier. Acasti Pharma Inc.’s shares saw a change of -91.53% in year-to-date performance and have moved 3.8% in past 5-day. It aims to treat heart disease by lowering LDL cholesterol, raising HDL (or ‘good’) cholesterol, and reducing triglycerides. Buy, Sell Or Hold Acasti Pharma Inc. (NASDAQ:ACST) At $0.21? There’s already one winner among omega-3 fish oil-based treatments, and there probably won’t be two. (That’s, of course, why cornstarch was chosen as a placebo in the first place.) Wall Street analysts have assigned a consensus price target of $1.26 to the stock, which implies a rise of 500% to its current value. Acasti likely will need more funding. Acasti Pharma Stock Plunges. For patients who are not hospitalized but are at risk of being critically ill... On Monday 9 November, the United States' primary stock indices showed an upward trend in the trading due to the results of the presidential... Netflix Inc. (NFLX) is expanding rapidly in the markets of India, Japan, Indonesia, and South Korea. Company’s recent per share price level of $0.21 trading at $0.01 or 2.85% at ring of the bell on the day assigns it a market valuation of $19.77 Million. Nasdaq There is some modest cause for hope with CaPre. Acasti Pharma generates negative expected return over the last 30 days: Acasti Pharma has high historical volatility and very poor performance: Acasti Pharma has some characteristics of a very speculative penny stock: The company reported the previous year's revenue of 20.75 K.Net Loss for the year was (21.33 M) with profit before overhead, payroll, taxes, and interest of 34.18 K. Acasti Pharma stock plunged this month after disappointing topline results in a key study of its CaPre cardiovascular drug candidate. Article printed from InvestorPlace Media, CaPre is an omega-3 phospholipid derived from fish oil. That audit will push back results from TRILOGY 2 into February, but results there give the company another chance to prove statistical significance and get CaPre back on track. But CaPre actually worked. The results this month were concerning, and the path to approval of CaPre is narrow. Wall Street analysts have assigned a consensus price target of $1.26 to the stock, … Copyright © 2020 InvestorPlace Media, LLC. There’s no guarantee that TRILOGY 2 will be successful. Acasti Pharma Inc.’s shares saw a change of -91.53% in year-to-date performance and have moved 3.8% in past 5-day. Monday’s close was ACST’s lowest close since 2018. Results from a second trial are due next month. LONDON (dpa-AFX) - Today's Daily Dose brings you news about Acasti Pharma's phase III trial of CaPre, Merger Monday, CorMedix's regulatory catalyst, Vanda Pharma's anticipated milestones, and Acasti is running “a full audit” of the data to try and understand what happened. In a research note, Mackie wrote that the market is 'waking up' to the potential of CaPre, which treats severe hypertriglyceridemia. None analyst(s) advised it as an Underweight. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.59 Million shares which gives us an average trading volume of 11.86 Million if we extend that period to 3-months. Investor confidence shakens after Alcoa Corporation (NYSE:AA) share prices loss -$0.05, Shares in Lumen Technologies, Inc. (LUMN) -26.72 % down, YTD. Number of shares sold short was 1.09 Million shares which calculate 0.18 days to cover the short interests. Amarin has projected peak annual sales in the “multiple billions“. In other words, a 96.12% loss. IA "Marketing Sentinel" seeks to provide the news and analytical information to both American and foreign audiences, events and events in the USA and all over the world reliably, objectively and promptly. Rival Amarin (NASDAQ:AMRN) has seen its stock soar thanks to strong results for its recently approved Vascepa. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. DOW 0.00%. Cancel. Strategies like duplicating content in local languages, creating... Goldman Sachs cuts growth forecasts due to intense 2nd wave of Coronavirus and fear that it may get worst during the winter season. TRILOGY 1 results didn’t reach statistical significance against placebo. As the company itself noted, if Acasti Pharma can find a “plausible explanation” for the placebo performance in TRILOGY 1, and can prove statistical significance in TRILOGY 2, there’s still “a path forward” to a New Drug Application with the FDA. 1125 N. Charles St, Baltimore, MD 21201. S&P 500 0.00%. In similar trials, the effect usually was in a range between -10% and +10%. That latter performance doesn’t seem to make much sense. Acasti Pharma (NASDAQ:ACST) is a classic example of the extreme volatility of small-cap biotech stocks. The placebo is just cornstarch, which should have zero effect. Traum-Renditen mit Lithium: Trading-Chance des Monats! Real-time trade and investing ideas on Acasti Pharma Inc. ACST from the largest community of traders and investors. Brookdale Senior Living Inc. (NYSE:BKD) up 3.62% over the past 30 days: Any Troubles Ahead? Stranger things have happened, and risk-loving investors might see Acasti Pharma stock differently.